journal
MENU ▼
Read by QxMD icon Read
search

Nature Reviews. Clinical Oncology

journal
https://read.qxmd.com/read/30733593/challenges-to-curing-primary-brain-tumours
#1
REVIEW
Kenneth Aldape, Kevin M Brindle, Louis Chesler, Rajesh Chopra, Amar Gajjar, Mark R Gilbert, Nicholas Gottardo, David H Gutmann, Darren Hargrave, Eric C Holland, David T W Jones, Johanna A Joyce, Pamela Kearns, Mark W Kieran, Ingo K Mellinghoff, Melinda Merchant, Stefan M Pfister, Steven M Pollard, Vijay Ramaswamy, Jeremy N Rich, Giles W Robinson, David H Rowitch, John H Sampson, Michael D Taylor, Paul Workman, Richard J Gilbertson
Despite decades of research, brain tumours remain among the deadliest of all forms of cancer. The ability of these tumours to resist almost all conventional and novel treatments relates, in part, to the unique cell-intrinsic and microenvironmental properties of neural tissues. In an attempt to encourage progress in our understanding and ability to successfully treat patients with brain tumours, Cancer Research UK convened an international panel of clinicians and laboratory-based scientists to identify challenges that must be overcome if we are to cure all patients with a brain tumour...
February 7, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30723291/csf-dna-provides-a-snapshot-of-the-glioma-genome
#2
David Killock
No abstract text is available yet for this article.
February 5, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30718844/the-beginning-of-the-end-for-conventional-recist-novel-therapies-require-novel-imaging-approaches
#3
REVIEW
Mirjam Gerwing, Ken Herrmann, Anne Helfen, Christoph Schliemann, Wolfgang E Berdel, Michel Eisenblätter, Moritz Wildgruber
Owing to improvements in our understanding of the biological principles of tumour initiation and progression, a wide variety of novel targeted therapies have been developed. Developments in biomedical imaging, however, have not kept pace with these improvements and are still mainly designed to determine lesion size alone, which is reflected in the Response Evaluation Criteria in Solid Tumors (RECIST). Imaging approaches currently used for the evaluation of treatment responses in patients with solid tumours, therefore, often fail to detect successful responses to novel targeted agents and might even falsely suggest disease progression, a scenario known as pseudoprogression...
February 4, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30718843/comparing-and-contrasting-predictive-biomarkers-for-immunotherapy-and-targeted-therapy-of-nsclc
#4
REVIEW
D Ross Camidge, Robert C Doebele, Keith M Kerr
The era of personalized medicine for advanced-stage non-small-cell lung cancer (NSCLC) began when biomarker-based evidence of molecular pathway and/or oncogene addiction of the tumour became mandatory for the allocation of specific targeted therapies. More recently, the immunotherapy revolution, specifically, the development of immune-checkpoint inhibitors (ICIs), has dramatically altered the NSCLC treatment landscape. Herein, we compare and contrast the clinical development of immunotherapy and oncogene-directed therapy for NSCLC, focusing on the role of predictive biomarkers...
February 4, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30705439/regulatory-t-cells-in-cancer-immunosuppression-implications-for-anticancer-therapy
#5
REVIEW
Yosuke Togashi, Kohei Shitara, Hiroyoshi Nishikawa
Regulatory T (Treg ) cells, an immunosuppressive subset of CD4+ T cells characterized by the expression of the master transcription factor forkhead box protein P3 (FOXP3), are a component of the immune system with essential roles in maintaining self-tolerance. In addition, Treg cells can suppress anticancer immunity, thereby hindering protective immunosurveillance of neoplasia and hampering effective antitumour immune responses in tumour-bearing hosts, thus promoting tumour development and progression. Identification of the factors that are specifically expressed in Treg cells and/or that influence Treg cell homeostasis and function is important to understanding cancer pathogenesis and to identifying therapeutic targets...
January 31, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30700859/real-world-data-towards-achieving-the-achievable-in-cancer-care
#6
REVIEW
Christopher M Booth, Safiya Karim, William J Mackillop
The use of data from the real world to address clinical and policy-relevant questions that cannot be answered using data from clinical trials is garnering increased interest. Indeed, data from cancer registries and linked treatment records can provide unique insights into patients, treatments and outcomes in routine oncology practice. In this Review, we explore the quality of real-world data (RWD), provide a framework for the use of RWD and draw attention to the methodological pitfalls inherent to using RWD in studies of comparative effectiveness...
January 30, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30692650/hybrid-minimally-invasive-surgery-overtakes-open-surgery
#7
Diana Romero
No abstract text is available yet for this article.
January 28, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30675022/rectal-cancer-not-a-waiting-game
#8
David Killock
No abstract text is available yet for this article.
January 23, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30670830/approvals-in-2018-a-histology-agnostic-new-molecular-entity-novel-end-points-and-real-time-review
#9
Gideon M Blumenthal, Richard Pazdur
No abstract text is available yet for this article.
January 22, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30664678/crispr-cas-a-tool-for-cancer-research-and-therapeutics
#10
REVIEW
Hao Yin, Wen Xue, Daniel G Anderson
In the past decade, the development of a genome-editing technology mediated by CRISPR has made genetic engineering easier than ever, both in vitro and in vivo. CRISPR systems have enabled important advances in cancer research by accelerating the development of study models or as a tool in genetic screening studies, including those aiming to discover and validate therapeutic targets. In this Review, we discuss these applications as well as new potential uses of CRISPR to assist in cancer detection or the development of anticancer therapies...
January 21, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30664677/desmoid-tumours-stalled-by-sorafenib
#11
Katharine H Wrighton
No abstract text is available yet for this article.
January 21, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30659285/folfirinox-goes-adjuvant
#12
Diana Romero
No abstract text is available yet for this article.
January 18, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30647429/towards-risk-stratified-induction-regimens
#13
David Killock
No abstract text is available yet for this article.
January 15, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30644455/truly-personalized-therapy-an-end-to-the-era-of-one-size-fits-all
#14
Nadia Harbeck, Rachel Wuerstlein
No abstract text is available yet for this article.
January 15, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30617343/reshaping-the-critical-role-of-surgeons-in-oncology-research
#15
REVIEW
Robert P Jones, Chandrakanth Are, Thomas J Hugh, Dirk J Grünhagen, Jianmin Xu, Charles M Balch, Graeme J Poston
Surgery remains a mainstay in the treatment of most solid cancers. Surgeons have always engaged in various forms of high-quality cancer research to optimize outcomes for their patients, for example, contributing to clinical research and outcomes research as well as health education and public health policy. Over the past decade, however, concerns have been raised about a global decline in the number of surgeons performing basic science research alongside clinical activity - so-called surgeon scientists. Herein, we describe some of the unique obstacles faced by contemporary trainee and practising surgeons engaged in research, as well as providing a perspective on the implications of the diminishing prominence of the surgeon scientist...
January 7, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30604778/t-dm1-protects-against-invasive-disease
#16
Peter Sidaway
No abstract text is available yet for this article.
January 3, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30602757/echelon-2-brentuximab-raises-ptcl-outcomes-to-new-levels
#17
David Killock
No abstract text is available yet for this article.
January 2, 2019: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30575811/two-steps-forward-and-one-step-back
#18
Florian Lordick, Elizabeth C Smyth
No abstract text is available yet for this article.
December 21, 2018: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30575810/alliance-to-illuminate-the-chemo-free-sign
#19
Diana Romero
No abstract text is available yet for this article.
December 21, 2018: Nature Reviews. Clinical Oncology
https://read.qxmd.com/read/30573793/setting-dictates-efficacy-of-pembrolizumab-in-tnbc
#20
Peter Sidaway
No abstract text is available yet for this article.
December 20, 2018: Nature Reviews. Clinical Oncology
journal
journal
20200
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"